Bristol-Myers Squibb
BMS’ Opdivo+Yervoy combo fails in small cell lung cancer
November 27, 2018Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …
FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival
November 7, 2018Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma
The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …
BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients
October 22, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo
American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …
BMS’ Opdivo fails to improve overall survival in small-cell lung cancer
October 15, 2018Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma
Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, …
Top Ten most popular articles on Pharmafile.com this week
September 14, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, FDA, NICE, Novo Nordisk, Spinraza, brexit, bristol myers squibb, top 10
With the Pharmafocus team having avoided hurricane Florence and finally arriving back in the UK just last night, after stopping …
BMS’ investigational psoriasis drug hits primary endpoint in skin clearance at Phase 2
September 12, 2018Research and Development BMS, BMS-986165, Bristol-Myers Squibb, pharma, psoriasis
Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …
Bristol-Myers Squibb appoints Christopher Boerner as new Executive Vice President and Chief Commercial Officer
August 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, bristol myers squibb, cco, chief commercial officer, christopher boerner, executive vice president, murdo gordon
Bristol Myers Squibb has announced that Dr Christopher Boerner will take over from Murdo Gordon as executive Vice President and …
FDA approves Bristol Myers Squibb’s Opdivo in small-cell lung cancer
August 20, 2018Sales and Marketing Bristol-Myers Squibb, FDA, approval, bristol myers squibb, lung cancer, opdivo
The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) for patients with metastatic small-cell lung cancer (SCLC), as the first …
Bristol Myers Squibb announces departure of Chief Commercial Officer
July 24, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, bristol myers squibb, commerical executive, marketing, sales
Bristol Myers Squibb has announced that Executive Vice President and Chief Commercial Officer, Murdo Gordon, who has been with the …
NICE turns down BMS’ blockbuster Opdivo for urothelial carcinoma
July 5, 2018Sales and Marketing BMS, Bristol-Myers Squibb, NICE, opdivo, pharma, urothelial carcinoma
Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to …
The July/August issue of Pharmafocus is now live!
July 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Elizabeth Holmes, NHS, Sanofi, Theranos, UK, ambien, manufacturing compliance, opdivo, patient recruitment, patient retention, pharma
The new July/August edition of Pharmafocus is now available to read online.
Cadila scores FDA approval for BMS and Alvogen generics
July 3, 2018Manufacturing and Production, Sales and Marketing Adolat, Alvogen, Bristol-Myers Squibb, Cadila, FDA, Questran, generics, pharma
Cadila Healthcare has announced that it has gained FDA final approval to market nifedipine ER tablets in the strengths of …
BMS’ Opdivo becomes first immuno-oncology agent available in China
June 18, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma
Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …
“Underwhelming” drug data devastates Nektar, shares fall by 42%
June 5, 2018Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma
Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …
New cancer clinical trial model promises to cut costs and development time
May 15, 2018Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, Cancer, MD AndersonCancer Center, clinical trials, pharma
Researchers from the University of Texas MD Anderson Cancer Center have been developing and testing a new model for the …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
